| Similar Articles |
|---|
 |
BusinessWeek
December 13, 2004
Gene G. Marcial |
Rich Suitors May Come Courting Curis With Genentech, Johnson & Johnson, and Wyeth as its partners, tiny Curis is a "sitting duck" for a takeover as it develops drugs to combat a number of diseases. One hedge-fund manager puts Curis' buyout value at $9 a share.   |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
The Motley Fool
June 21, 2011
Brian Orelli |
Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen. |
The Motley Fool
February 9, 2011
Rich Smith |
What's Behind the Run-Up at Curis? One word: earnings. |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
BusinessWeek
May 16, 2005
Arlene Weintraub |
Bristling With Promise Start-up Curis is developing a class of drugs that could halt hair loss -- and treat cancer |
